Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- olutasidenib
- lazertinib
Interactions between your drugs
olutasidenib lazertinib
Applies to: olutasidenib, lazertinib
MONITOR: Coadministration with weak inducers of CYP450 3A4 may reduce the plasma levels and effects of lazertinib, which is primarily metabolized by the isoenzyme. In a phase 1 study of healthy adult participants, concomitant use of the strong CYP450 3A4 inducer rifampin reduced the peak plasma concentration (Cmax) and systemic exposure (AUC) of lazertinib by 72% and 83%, respectively. Likewise, a pharmacokinetic model predicted that concomitant use with the moderate CYP450 3A4 inducer efavirenz would decrease lazertinib's steady state Cmax and AUC by at least 32% and 44%, respectively. Clinical data with less potent CYP450 3A4 inducers are not available.
MANAGEMENT: The potential for diminished pharmacologic effects of lazertinib should be considered if coadministration with a weak CYP450 3A4 inducer is clinically necessary. An alternative concomitant medication with no potential to induce CYP450 3A4 may be required.
References (2)
- (2024) "Product Information. Lazcluze (lazertinib)." Janssen Biotech, Inc.
- Janssen Research & Development, LLC (2024) A study to assess the effects of itraconazole and rifampin on lazertinib in healthy adult participants. https://clinicaltrials.gov/study/NCT04410094?tab=table
Drug and food interactions
olutasidenib food
Applies to: olutasidenib
ADJUST DOSING INTERVAL: Coadministration with a high-fat meal may increase the plasma concentrations of olutasidenib. According to the product labeling, administration of a single 150 mg dose with a high-fat meal (approximately 800 to 1000 calories, with approximately 50% of those calories from fat) increased olutasidenib peak plasma concentration (Cmax) and systemic exposure (AUC) by 191% and 83%, respectively, in healthy subjects.
MANAGEMENT: Olutasidenib should be administered at about the same time each day, on an empty stomach at least 1 hour before or 2 hours after a meal.
References (1)
- (2022) "Product Information. Rezlidhia (olutasidenib)." Rigel Pharmaceuticals
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Vidaza
Vidaza is used to treat certain types of bone marrow cancers and blood cell disorders. Learn about ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Xospata
Xospata (gilteritinib) is used to treat acute myeloid leukemia (AML) with a FLT3 mutation. Xospata ...
Revuforj
Revuforj is used to treat acute leukemia with a lysine methyltransferase 2A gene translocation ...
Vanflyta
Vanflyta (quizartinib) is an oral targeted treatment called a kinase inhibitor that may be used to ...
Idhifa
Idhifa (enasidenib) is used to treat acute myeloid leukemia in adults who have a mutation in the ...
Onureg
Onureg (azacitidine) is used for the continued treatment of adult patients with acute myeloid ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.